Proteomic profiling and machine learning for endotype prediction in chronic rhinosinusitis
- PMID: 40939758
- DOI: 10.1016/j.jaci.2025.08.025
Proteomic profiling and machine learning for endotype prediction in chronic rhinosinusitis
Abstract
Background: Chronic rhinosinusitis (CRS) is a common, heterogeneous upper airway inflammatory disorder, affecting approximately 12% of the general population. The disease is clinically stratified into CRS without nasal polyps and CRS with nasal polyps, including the most severe subtype of nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD).
Objective: To identify molecular signatures and biomarkers allowing for the distinction between different disease endotypes and controls, we used targeted proteomics combined with bioinformatics and machine learning analyses.
Methods: Nasal secretions and serum from 80 patients (20 each of CRS without nasal polyps, CRS with nasal polyps, N-ERD, and disease controls) were subjected to high-throughput targeted proteomics (Olink). The expression patterns of 161 and 2677 proteins, for nasal secretions and serum, respectively, were analyzed alongside clinical evaluations of nasal polyp and smell test scores.
Results: Two distinct expression patterns were identified in nasal secretions: proteins associated with macrophage recruitment and type 2 inflammation were increased in CRS with nasal polyps and N-ERD, whereas proteins associated with innate immunity, particularly Toll-like receptor 4 signaling, were gradually downregulated from disease control to N-ERD. Furthermore, using machine learning, we confirmed 2 potential biomarkers for nasal polyposis: the glial cell line-derived neurotrophic factor in nasal secretions and Charcot-Leyden crystal protein in serum.
Conclusions: Our findings provide unique insights into CRS pathophysiology and highlight potential biomarkers for precision diagnosis and treatment, particularly in severe cases such as N-ERD.
Keywords: Nasal polyposis; biomarker; machine learning; type 2 inflammation.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure statement This project was funded by GlaxoSmithKline (GSK ISS 219630). M.Z. received funding from the Austrian Science Fund (FWF; grant no. KLP4891723). Disclosure of potential conflict of interest: S. Schneider served as a speaker and/or consultant and/or advisory board member for Sanofi, GlaxoSmithKline (GSK), and Novartis and investigator for Novartis, GSK, and AstraZeneca (grants paid to his institution). J. Eckl-Dorna served as a speaker and/or consultant and/or advisory board member and investigator for Sanofi, AstraZeneca, and GSK (grants paid to her institution). The rest of the authors declare that they have no relevant conflicts of interest.
LinkOut - more resources
Full Text Sources
